Lytenava is a monoclonal antibody commercialized by Outlook Therapeutics, with a leading Pre-Registration program in Wet (Neovascular / Exudative) Macular Degeneration. According to Globaldata, it is involved in 7 clinical trials, of which 3 were completed, 1 is ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Lytenava’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Lytenava is expected to reach an annual total of $1.03 bn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Lytenava Overview

Bevacizumab-vikg is under development for the treatment of wet age related macular degeneration, diabetic macular edema, branch retinal vein occlusion and other retinal diseases. The drug candidate is a monoclonal antibody developed based on Biosymphony platform. It is administered through intravitreal route in the form of solution. It acts by targeting vascular endothelial growth factor A (VEGFA).

Outlook Therapeutics Overview

Outlook Therapeutics is a biopharmaceutical company. It develops, manufactures, and commercializes biosimilar products in the areas of ophthalmology. The company pipeline product includes ONS-5010 Lytenava, Repackaged Bevacizumab, Ophthalmic anti vegf among others. The company is investigating its lead product candidate, ONS-5010 an ophthalmic formulation of bevacizumab-VIKG intended to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), branch retinal vein occlusion (BRVO) and other retinal diseases. It works in collaboration with biotechnology and pharmaceutical companies to develop its products. Outlook Therapeutics is headquartered in Cranbury, New Jersey, the US.

The operating loss of the company was US$64.1 million in FY2022, compared to an operating loss of US$51.7 million in FY2021. The net loss of the company was US$66.1 million in FY2022, compared to a net loss of US$53.2 million in FY2021.

For a complete picture of Lytenava’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.